Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: Reuters Investment Profile
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bionomics Ltd Announces Underwritten Rights Issue

Sunday, 3 Mar 2013 05:25pm EST 

Bionomics Ltd announced a 1 for 8 non-renounceable rights issue at AUD 0.36 per New Share to raise up to approximately AUD 16.4 million before costs (The Offer). The Offer is fully underwritten by Lead Manager Bell Potter Securities Limited. Funds from the capital raising will be used to advance development programs across Bionomics' pipeline, including BNC375, Bionomics' drug candidate for the treatment of Alzheimer's disease and other conditions where memory is compromised and Bionomics' cancer stem cell directed drug candidate BNC101. The Offer will result in the issue of up to approximately 45.6 million New Shares, taking Bionomics' total issued ordinary share capital to approximately 410.7 million Shares. 

Company Quote

-0.01 -2.00%
24 Jul 2014